SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as investors focus on an upcoming earnings report, with the community actively debating whether the company can maintain its rapid growth despite concerns over increased competition from store-brand alternatives and broader margin pressures. While some investors express frustration over recent price volatility and potential institutional manipulation, others remain bullish on the long-term potential of the PepsiCo distribution partnership and the successful integration of Alani Nu.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing extreme volatility and a sharp sell-off as investors re-evaluate the stock following its rapid appreciation and news regarding the competitive landscape for edge AI agents. The community is deeply divided, with many traders debating whether this is a structural failure or a temporary overreaction offering a bargain buy-the-dip opportunity for the long term.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending as investors react to a significant data center campus development in Thailand and an expanded partnership with Yotta, fueling speculation about long-term revenue potential and a possible short squeeze due to high short interest and a limited tradable float. The community is actively debating the legitimacy of these massive contract announcements and the company's ability to finance them, with many longs expressing high conviction in the stock's future as it attempts to break through key technical resistance levels.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is generating significant buzz as traders closely watch its upcoming earnings report, with the community split between betting on a massive breakout driven by AI-powered ad revenue and fears of volatility and manipulation. The stock remains a polarizing focal point as investors debate whether current software sector headwinds or the company's strong fundamentals and buyback activity will dictate the next major price move.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant leadership overhaul that replaced the former CEO with Chairman Kevin Tang, sparking optimism for a potential buyout. The community is actively debating the strategic implications of Tangs aggressive management style and the company's recent acquisition of Kezar Life Sciences as key catalysts for future value creation.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors react to a quarterly report that beat estimates for revenue and free cash flow but triggered concerns over North American user growth and conservative guidance. The community is sharply divided between those betting on a long-term turnaround fueled by cost-cutting and potential AI integration, and others venting frustration over stagnant share performance and perceived leadership failures.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is currently trending following a report identifying the company as a key stealth supplier for Nvidia and Apple's advanced optical infrastructure, specifically regarding wafer-level optics for Co-Packaged Optics. The community is actively debating the sustainability of this price action, with some investors pointing to long-term growth in AI data center components, while skeptics caution against potential volatility and speculative hype.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant investor attention driven by a combination of strong institutional backing through recent AAA-rated bond deals and anticipation surrounding their upcoming first-quarter earnings report. While the community is actively debating the stock's valuation versus its underlying AI-driven credit underwriting model, many long-term holders remain focused on the company's sustained GAAP profitability and a growing network of financial partners.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing significant volatility as market participants react to a resale registration filing that increases the number of shares available for trading. While some investors are concerned about potential supply overhang and the company's early-stage financials, the community is actively debating whether this sell-off is an overreaction or a structural reset for the quantum infrastructure play.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending due to the company securing a $21 million purchase order for its SiCore cylindrical batteries from a major new electric mobility customer in China. Investors are closely monitoring the stock's price action as it attempts to maintain a sustained trading range above $18, which is a critical threshold for triggering the forced exercise of outstanding public warrants.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Oppenheimer &amp; Co. raised its ownership stake in Bitcoin miner TeraWulf by about 45% in the fourth quarter, bringing its total holdings to 140,101 shares, worth around $1.61 million.</li><li>Analysts anticipate revenue of about $34.25 million and a $0.16 per share quarterly loss.</li><li>Morgan Stanley has set a price target of $37, while broader analyst estimates range from $20 to $41.50.</li></ul>Oppenheimer &amp; Co (OPY) significantly increased its exposure to Bitcoin miner TeraWulf (WULF) in the first quarter of 2026, boosting its stake by over 45% as institutional interest in crypto-linked infrastructure continues to build.According to the SEC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/822581/000082258126000001/0000822581-26-000001-index.htm">filing</a>, the firm added 63,571 shares during the quarter, bringing total holdings to 203,672 shares, valued at approximately $2.94 million at the end of the period. Before the recent purchase, Oppenheimer &amp; Co. held 140,101 shares of TeraWulf at the end of the fourth quarter.&nbsp;<a href="https://stocktwits.com/symbol/WULF">WULF’s stock</a> was up over 6% during midday trading hours. On Stocktwits, the retail sentiment around WULF moved to the ‘extremely bullish’ from ‘bullish’ zone, while chatter around it shifted to ‘normal’ from ‘high’ over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_05_06_at_11_50_07_AM_png_85565e2201.webp" alt="Screenshot 2026-05-06 at 11.50.07 AM.png" width="940" height="100"><figcaption>HYPE retail sentiment and message volume on May 6 as of 11:50 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Analysts Remain Bullish On WULF</h2>Analysts remain generally bullish about TeraWulf, with Morgan Stanley commencing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-big-upside-wulf-cifr-mara-bitcoin-miners/cZBNsvQRePW">coverage</a> last month with an "Overweight" rating and a $37 price target, highlighting the company's potential in AI infrastructure.Wall Street's average price&nbsp;target for the company is now between $26 and $27, with some optimistic predictions pointing to a potential upside of $41.50, according to KoyfinAI. Analysts predict robust revenue growth for the Bitcoin miner and data center operator, with consensus forecasts of $326.8 million in FY2026 and roughly $975 million in FY2027, and $1.29 billion in FY2028.<h2 class="st-heading-2">Institutional Backing Strengthens Narrative</h2>Institutional support for TeraWulf has extended beyond Oppenheimer’s increased position. TeraWulf&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/04/16/3275801/0/en/TeraWulf-Announces-Closing-of-Common-Stock-Offering.html">entered</a> into an Underwriting Agreement with Morgan Stanley as representative of the underwriters for a public offering of common stock last month. The company sold 54,510,000 shares, including the overallotment, at $19.00 per share, generating approximately $1,004.3 million (roughly $1 billion) in net proceeds.<h2 class="st-heading-2">Short Squeeze Talk Builds As Positioning Tightens</h2>At the same time, market participants have increasingly pointed to positioning dynamics that could drive volatility. Some Stocktwits users&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.stocktwits.com/PittsburghTrader/message/652420084">noted</a> that both TeraWulf and Applied Digital (APLD) have been rallying in tandem.&nbsp;<stembedurl>https://stocktwits.com/PittsburghTrader/message/652420084</stembedurl>With both stocks moving higher simultaneously, the trader said the setup could increase pressure on overlapping short positions.Read also:<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-bearish-positioning-short-93000-squeeze-target/cZQz7VuReOB"> Bitcoin Bears Crowd In: Analysts Warn A Violent $93K Squeeze Could Be Next</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The TeraWulf logo appears on a smartphone screen and as the background on a laptop computer screen in this photo illustration in Athens, Greece, on September 3, 2025. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)

Oppenheimer Makes Big Bet On WULF With 45% Stake Increase — Retail Traders Lookout For A Short Squeeze

 As WULF stock shot up by over 6%, users on Stocktwits flagged potential short-squeeze risk amid bullish momentum.

Equity

As WULF stock shot up by over 6%, users on Stocktwits flagged potential short-squeeze risk amid bullish momentum.


<ul class="summary-bullets"><li>Tsai stated that Auvelity’s Q1 sales of $153 million exceeded consensus estimates for major depressive disorder.</li><li>The analyst believes the 2026 revenue estimate of $805 million for Auvelity is achievable, driven in part by a potential label expansion into Alzheimer’s agitation, which could boost sales in the second half of the year.</li><li>Deutsche Bank analyst David Hoang hiked his price target for Axsome, citing a positive outlook for Auvelity’s commercial launch and growth potential.</li></ul>Axsome Therapeutics Inc. (AXSM) reported a mixed first quarter on Monday, but analysts on Wall Street remain optimistic about the company’s prospects.According to TheFly, Jefferies analyst Andrew Tsai hiked the firm’s price target for Axsome to $275 from $245 while keeping a ‘Buy’ rating. The new price target implies an upside potential of nearly 21% from current levels.<a href="https://stocktwits.com/symbol/AXSM">Axsome Therapeutics shares</a> were up more than 10% in Monday morning’s trade. AXSM was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">Why Is Wall Street Bullish?</h2>Tsai stated that Auvelity’s Q1 sales of $153 million exceeded consensus estimates for major depressive disorder. The analyst believes the 2026 revenue estimate of $805 million for Auvelity is achievable, driven in part by a potential label expansion into Alzheimer’s agitation, which could boost sales in the second half of the year.Auvelity is Axsome’s treatment for agitation associated with dementia due to Alzheimer’s disease. Auvelity received a “clean label” approval from the U.S. Food and Drug Administration (FDA) last week, meaning that Auvelity will not carry a warning for increased risk of death in elderly patients with dementia.According to analysts at TD Cowen, this differentiates Auvelity from the only other approved therapy for ADA, Rexulti.Deutsche Bank analyst David Hoang raised the firm’s price target on Axsome Therapeutics to $281 from $245 and maintained a ‘Buy’ rating. Hoang cited a positive outlook for Auvelity’s commercial launch and growth potential as the reason for the price target hike.H.C. Wainwright analysts raised the firm’s price target on Axsome Therapeutics to $270 from $250 and maintained a ‘Buy’ rating, citing the FDA approval of Auvelity.<h2 class="st-heading-2">What Is Auvelity?</h2>Auvelity is an oral therapy targeting NMDA and sigma-1 receptors, having been approved in the U.S. for major depressive disorder and, more recently, for agitation associated with Alzheimer’s-related dementia.The company stated that about 223,000 prescriptions were written in Q1 2026, up 35% year-on-year and in line with fourth-quarter (Q4) levels. Axsome stated that payer coverage reached roughly 86% overall, including 78% in commercial plans and full coverage in Medicare and Medicaid.Following its FDA approval last week for Alzheimer’s agitation, the drug is set for a commercial launch in June. The company has also completed an expansion of its sales force to around 630 representatives, targeting a wide range of prescribers to support growth in both depression and Alzheimer’s-related use.<h2 class="st-heading-2">Axsome’s Mixed Q1</h2>Axsome Therapeutics’ Q1 results came in mixed on Monday. The company reported a loss of $1.26 per share, while Wall Street expected a loss of $0.86 per share, according to Fiscal.ai data.Axsome’s revenue came in at $191.2 million, edging past Wall Street’s estimates of $190.7 million.According to Koyfin data, the average 12-month price target for AXSM is $235.85, implying an upside of nearly 4% from current levels. Of the 20 analysts covering the stock, 19 have a ‘Buy’ or a ‘Strong Buy’ rating, while one has a ‘Hold’ recommendation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AXSM">Axsome Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.One bullish user expects Auvelity sales to reach at least $1.2 billion by the end of this year.<stembedurl>https://stocktwits.com/Georgejj/message/652182986</stembedurl>Another user thinks that big pharmaceutical companies are more willing than ever to acquire Axsome Therapeutics.<stembedurl>https://stocktwits.com/CloudMatt/message/652181828</stembedurl><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> is up 24% year-to-date and 102% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 27% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fnma-stock-in-focus-mizuho-fannie-mae-best-business-one-could-hope-for/cZQMvMpReJX">Mizuho Believes Fannie Mae Is Among The Best Businesses One Could Hope For — But Not Everyone Agrees</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism?

Jefferies analyst Andrew Tsai hiked the firm’s price target for Axsome to $275 from $245 while keeping a ‘Buy’ rating, implying an upside potential of nearly 21% from current levels.

<ul class="summary-bullets"><li>Ouster stated that major customers such as Google, Volvo Autonomous Solutions, and Liebherr intend to adopt the company’s latest family of lidar sensors.</li><li>The company added that these customers range from those operating in the automotive and robotics segments to those in the industrial and smart infrastructure markets.</li><li>Ouster stated that its Rev8 OS sensors are available to order starting Monday, with shipping scheduled to begin this quarter.</li></ul>Ouster Inc. (OUST) on Monday announced the next-generation family of lidar sensors, Rev8, featuring L4 Ouster Silicon.Ouster stated that the Rev8 family of lidar sensors features double the range and resolution over the prior generation. Rev8 also features the world’s first patented native color lidar sensors, according to the company.<a href="https://stocktwits.com/symbol/OUST">Ouster shares</a> were up more than 15% in Monday’s opening trade. OUST was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">Big Customers Lining Up, Says Ouster</h2>Ouster stated that some major customers, including Alphabet Inc.’s (GOOG, GOOGL) Google, Volvo Autonomous Solutions, and Liebherr, intend to adopt the company’s latest family of lidar sensors.The company added that these customers range from those operating in the automotive and robotics segments to those in the industrial and smart infrastructure markets.Ouster said its Rev8 OS sensors are available to order starting Monday, with shipping scheduled to begin this quarter.<h2 class="st-heading-2">Making Autonomous Driving Easier</h2>Ouster stated that the new Rev8 sensors unify structure and color to provide the full context necessary for autonomous driving, including road signs, interpret brake lights, and more.The company added that Rev8’s sensors capture megapixel-resolution data and assign color to each point at the hardware level, reducing delay and improving alignment. The single-sensor setup eliminates the need for complex calibration and provides combined 3D and color data, operating across lighting conditions from 1 lux to 2 million lux.“With the L4 Ouster Silicon, we are delivering on the promise of our digital architecture to deliver exponential improvements in performance, doubling our core specs and simultaneously introducing the world’s first native color lidar to give machines 3D human-like sight for the next era of Physical AI,” said Ouster CEO Angus Pacala.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OUST">Ouster</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.One bullish user stated that Ouster is building a company that will become the eyes of the AI era.<stembedurl>https://stocktwits.com/jpcalm68/message/652162441</stembedurl>Another user praised the new Rev8 sensors.<stembedurl>https://stocktwits.com/Moon_rocket69/message/652160277</stembedurl><a href="https://stocktwits.com/symbol/OUST">OUST stock</a> is up 37% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/OUST">GOOGL stock</a> is up 23%. The iShares Russell 2000 ETF (IWM) is up 42% over the past 12 months, while the Vanguard Information Technology Index Fund ETF (VGT) is up 50%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gamestop-ryan-cohen-ebay-build-larger-business-gme-ebay-stock/cZQMpRjReJc">Ryan Cohen Says GameStop Can Issue Additional Stock To Get eBay Deal Done — This Analyst Is Skeptical About The Synergies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The logo of Ouster Inc. is seen displayed on a smartphone

Ouster’s New Lidar Promises Human-Like Vision — And Big Names Are Already Lining Up

Ouster stated that the Rev8 family of lidar sensors features double the range and resolution over the prior generation.

<ul class="summary-bullets"><li>Overall net revenue from sales in Q1 was $8.3 million, the company said.&nbsp;</li><li>The company said that it now has funds to sustain itself till the second quarter of 2027.</li><li>Total net revenue from sales of Tonmya since launch through the end of the first quarter was $5.1 million. &nbsp;</li></ul> Shares of Tonix Pharmaceuticals (TNXP) fell 3% after hours after the company said that it expects a wider preliminary net loss for the first quarter of 2026 and revenue of $3.7 million for its newly launched drug Tonmya.The company said on Friday that it expects a Q1 net loss of about $40.8 million compared to a loss of $16.8 million for the corresponding quarter of 2025.<h2 class="st-heading-2">TNXP’s Preliminary Numbers</h2>Q1 net revenue from sales of its treatments Zembrace SymTouch, and Tosymra for the quarter ended March 31, 2026, was approximately $3.2 million, compared to $2.4 million for the quarter ended March 31, 2025.Net revenue from sales of Tonmya for the quarter was approximately $3.7 million. Tonmya, an FDA-approved, non-opioid medication designed to treat fibromyalgia in adults, was launched in November 2025.Total net revenue from sales of Tonmya since launch through the end of the first quarter was $5.1 million, Tonix said. &nbsp;The company said that it ended the first quarter with about $185.5 million in cash and cash equivalents, which, together with net proceeds of $17.4 million that it raised in April 2026 to be enough to sustain it till the second quarter of 2027.The company is now slated to report its full financial results on May 11.<h2 class="st-heading-2">How Did TNXP Retail Traders React?</h2>On Stocktwits, retail sentiment around TNXP stock stayed in the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user opined that the numbers put forth by Tonix are being “misunderstood” and Tonmya launch is not “as weak as it appears.”<stembedurl>https://www.stocktwits.com/ltinvestorx/message/652073834</stembedurl>Another user opined that the company entered 2026 with real momentum and a stronger balance sheet than many of its small-cap biotech peers.<stembedurl>https://www.stocktwits.com/ACMTrader/message/652072480</stembedurl><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> fell 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/celc-stock-jumps-after-hours-on-positive-breast-cancer-trial-update/cZQ8HuEReeM">CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug

The company said on Friday that it now expects a net loss for the first quarter of about $40.8 million compared to a loss of $16.8 million for the corresponding quarter of 2025.

<ul class="summary-bullets"><li>Wall Street expects SoundHound AI to report a loss of $0.01 per share in the first quarter, narrowing from a loss of $0.09 per share during the same period a year ago, according to Fiscal.ai data.</li><li>Analysts expect the company to report a 40% year-on-year revenue surge to $42.56 million.</li><li>SoundHound AI is set to report its Q1 earnings on May 7, after the closing bell.</li></ul>Shares of SoundHound AI Inc. (SOUN) have barely managed to cross the 200-day moving average (200-DMA) just once in 2026 so far, and with first-quarter earnings approaching, the stock still remains more than 41% below the average line.<a href="https://stocktwits.com/symbol/SOUN">SoundHound AI shares</a> were up nearly 6% in Friday morning’s trade, after ending April with gains of nearly 16%.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_05_01_at_10_27_30_AM_png_f72c62460a.webp" alt="Screenshot 2026-05-01 at 10.27.30 AM.png" width="3322" height="1814"><figcaption>Source: TradingView</figcaption></figure><h2 class="st-heading-2">What Is Wall Street Expecting?</h2>Wall Street expects SoundHound AI to report a loss of $0.01 per share during the first quarter (Q1), narrowing from a loss of $0.09 per share during the same period a year ago, according to Fiscal.ai data.Analysts expect the company to report a 40% year-on-year revenue surge to $42.56 million during the first quarter.SoundHound AI has a mixed record with Wall Street estimates. While its earnings have beaten estimates in two of the previous four quarters, its revenue has surpassed expectations in three of the past four quarters.SoundHound AI is set to report its Q1 earnings on May 7, after the closing bell.<h2 class="st-heading-2">SoundHound Expands Partnership With Casey’s</h2>SoundHound AI announced an expansion of its partnership with Casey’s last month, allowing the convenience retailer and pizza chain to deploy technology that can answer incoming calls from customers automatically.The company stated that its AI agents can also answer menu-related questions and provide information about ongoing promotions and specials in Casey’s stores.SoundHound AI also announced last month that it had entered into a definitive agreement to acquire LivePerson Inc. (LPSN) for an equity value of $43 million. The company stated that it expects to generate at least $350 million to $400 million in revenue in 2027, including a minimum contribution of $100 million from LivePerson’s long-tenured customers.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/SOUN">SoundHound AI</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels at the time of writing.One bullish user on the platform stated that, in the past, a rally in SOUN stock has begun three days before earnings.<stembedurl>https://stocktwits.com/mcae/message/651981966</stembedurl>Another user stated that investors should expect some turbulence in the stock before a rally.<stembedurl>https://stocktwits.com/kingofking719/message/652016012</stembedurl><a href="https://stocktwits.com/symbol/SOUN">SOUN stock</a> is down 16% year-to-date and 8% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 42% over the past 12 months, while the Vanguard Small-Cap Index Fund ETF (VB) is up 31%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tmc-stock-gains-noaa-compliance-ruling-us-critical-metals-push/cZQV7ANReeg">TMC Stock Gains On NOAA Compliance Ruling In A Boost To US Critical Metals Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of SoundHound AI, Inc. is displayed on a smartphone screen.

SOUN Stock Has Barely Managed To Nudge Its 200-DMA In 2026 Just Once — Will Q1 Earnings Take It There?

Shares of SoundHound AI rose nearly 6% in Friday morning trading after gaining about 16% in April, but the stock still needs to climb more than 41% to reclaim its 200-day moving average.

iShares Russell 2000 ETF Experiences Big Outflow

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 ETF (Symbol: IWM) where we have detected an approximate $1.8 billion dollar outflow -- that's a 2.4% decrease week over week (f...

<ul class="summary-bullets"><li>Bloom Energy’s revenue in the quarter ended March 31 surged 130% year-over-year to $751.1 million, above a Wall Street estimate of $540.02.</li><li>The strong start to 2026 comes as the company continues to convert a sizable backlog into deployments across data centers, semiconductor fabs, utilities, and commercial-industrial sites.</li><li>Bloom also lifted its 2026 revenue guidance to a range of $3.4 billion to $3.8 billion — implying roughly 80% year-over-year growth at the midpoint, up from a prior outlook of about 60%.</li></ul> Shares of Bloom Energy (BE) rose 13% after-hours on Tuesday after it reported explosive first-quarter growth and significantly raised its full-year outlook Tuesday, with founder and CEO KR Sridhar declaring the company is rapidly becoming the standard choice for on-site electricity at data centers and other mission-critical facilities.Year-to-date, the stock has already more than doubled on AI-power tailwinds.The results underscore how the artificial-intelligence boom is reshaping power infrastructure: hyperscalers and data-center operators are turning to Bloom’s on-site fuel-cell systems to bypass grid delays and secure the electricity needed for AI training and inference workloads.<h2 class="st-heading-2">Quarterly Numbers</h2>Bloom Energy’s revenue in the quarter ended March 31 surged 130% year-over-year to $751.1 million, driven by a 208% jump in product revenue to $653.3 million, above a Wall Street estimate of $540.02. Adjusted and diluted earnings per share for the quarter came in at $0.44, above an estimated $0.13.Bloom ended the quarter with $2.49 billion in cash and equivalents and generated $73.6 million in operating cash flow, a sharp turnaround from the prior-year outflow. The strong start to 2026 comes as the company continues to convert a sizable backlog into deployments across data centers, semiconductor fabs, utilities, and commercial-industrial sites.<h2 class="st-heading-2">Bloom Energy’s Guidance</h2>Bloom also lifted its 2026 revenue guidance to a range of $3.4 billion to $3.8 billion — implying roughly 80% year-over-year growth at the midpoint, up from a prior outlook of about 60%. Adjusted operating income guidance was set at $600 million to $750 million, with adjusted EPS expected between $1.85 and $2.25.“We at Bloom are ushering in the era of digital power for the digital age,” Sridhar said in prepared remarks. “Bloom is rapidly becoming the standard and ‘go-to choice’ for on-site power.”The company’s momentum has been fueled by major deals tied directly to AI expansion. It recently expanded a partnership with Oracle to deploy up to 2.8 gigawatts of Bloom systems, and it was named the preferred on-site power provider for Brookfield’s AI-factory investments.<h2 class="st-heading-2">How Did Retail Traders React To BE?</h2>On Stocktwits, retail sentiment around BE stock rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levelsA Stocktwits user opined that the stock will open in the green on Wednesday, too.<stembedurl>https://www.stocktwits.com/ScissorHands_/message/651680225</stembedurl>Another user opined that the company’s revenues are still low for its current stock price.<stembedurl>https://www.stocktwits.com/BullrunBull/message/651679918</stembedurl><a href="https://stocktwits.com/symbol/BE">BE stock</a> has rallied 1077% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-says-he-is-openai-shareholder-dismisses-reports-of-company-missing-targets/cZBo7mKRedx">‘Pharma Bro’ Martin Shkreli Says He Is An OpenAI Shareholder, Dismisses Reports Of Company Missing Targets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bloom Energy (Be) logo is seen displayed on a smartphone screen. 

BE Stock Soars After-Hours As Rising AI Infrastructure Boosts Full-Year Power Demand Outlook

The company’s momentum has been fueled by major deals tied directly to AI expansion. 

<ul class="summary-bullets"><li>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections.</li><li>Rezzayo is already approved in the U.S. for the treatment of candidemia and invasive candidiasis in adults.</li><li>The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.</li></ul>Shares of CorMedix Therapeutics (CRMD) rose 2% on Monday after the company announced positive results from its late-stage trial evaluating its antifungal drug Rezzayo to prevent invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Allogeneic hematopoietic stem cell transplantation is a curative procedure for high-risk blood cancers and marrow diseases, where healthy blood-forming cells from a donor replace a patient's diseased marrow. Patients undergoing the procedure face prolonged periods where their immunity is not strong enough to ward off infections from fungi, including candida, aspergillus, and pneumocystis.Rezzayo is already approved in the U.S. for the treatment of fungal infections, candidemia, and invasive candidiasis in adults. The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.<h2 class="st-heading-2">Trial Takeaways</h2>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections, the company said. Fungal-free survival at day 90 was 60.7% in the Rezzayo group versus 59.0% in the group that received a standard antimicrobial regimen, it added.Furthermore, the drug was well tolerated with a safety profile showing a favorable benefit/risk profile in the patient population, the company said, while adding that the drug also demonstrated fewer interactions with other drugs and discontinuations due to toxicity.CorMedix now expects to have a meeting with the U.S. Food and Drug Administration in the coming months before submitting an application for the drug for the indication. The company expects to file the application in the second half of 2026 based on the trial results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CRMD jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels. According to internal data, retail chatter around the stock jumped 1400% over the past day.A Stocktwits user expressed optimism for the stock rising into earnings while adding that “today was great news.”<stembedurl>https://www.stocktwits.com/S2730/message/651521499</stembedurl>Another user expressed muted enthusiasm, opining that the results, though good, are not “transformative.”<stembedurl>https://www.stocktwits.com/ReturnOfEsquire/message/651515352</stembedurl> <a href="https://stocktwits.com/symbol/CRMD">CRMD stock</a> has fallen 17% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sndk-stock-surges-nearly-8-to-hit-fresh-record-high-what-s-behind-the-investor-optimism-april-27/cZBND2dReP8">SNDK Stock Surges Nearly 8% To Hit Fresh Record High – What’s Behind The Investor Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market 

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 

<ul class="summary-bullets"><li>BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.</li><li>The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.</li><li>Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while adding that the company now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.</li></ul>Shares of Oruka Therapeutics Inc. (ORKA) were on track for their best single-day gains in more than a month after the company announced interim results from a trial of its moderate-to-severe plaque psoriasis therapy.Oruka Therapeutics announced that 40 of the 63 participants in the EVERLAST-A Phase 2a trial of ORKA-001, a novel, half-life-extended IL-23p19 monoclonal antibody, met the primary endpoint.<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics shares</a> were up more than 20% in Monday’s opening trade.<h2 class="st-heading-2">BTIG Turns Bullish On Oruka</h2>According to TheFly, analysts at BTIG turned bullish on Oruka Therapeutics following the company’s interim trial results. The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.BTIG stated that ORKA-001 has strong potential to become the preferred IL-23 inhibitor if approved, citing best-in-class efficacy and roughly one-fourth the maintenance injection burden of AbbVie’s (ABBV) Skyrizi.Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while keeping a ‘Buy’ rating on the stock. The firm believes ORKA-001 has multi-billion-dollar blockbuster potential, adding that Oruka now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.<h2 class="st-heading-2">Oruka’s Findings In The Trial</h2>Oruka stated that 64% of the participants in the trial achieved complete skin clearance in the 16th week.The company stated that key secondary endpoints were also strong, with 83% reaching PASI 90 during this period.In the placebo group, one of 21 participants met these endpoints, which it said was consistent with historical psoriasis trials.Oruka stated that cross-trial comparisons suggest ORKA-001 delivers higher skin clearance rates than other IL-23p19 inhibitors and ranks among the best reported in plaque psoriasis across all treatment types.The company stated that it plans to release longer-term EVERLAST-A data in the second half of 2026, including Week 28 results for all patients, along with a 52-week follow-up for a subset. Oruka also added that it will continue to advance the Phase 2b EVERLAST-B trial, with data expected in 2027.PASI refers to the Psoriasis Area and Severity Index. It quantifies the severity and extent of psoriasis symptoms across body regions. PASI 90 refers to a 90% or more improvement. Similarly, PASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels as of this writing.One bullish user believes ORKA stock could reach $200 per share soon.<stembedurl>https://stocktwits.com/Chiefstaff/message/651484000</stembedurl><a href="https://stocktwits.com/symbol/ORKA">ORKA stock</a> is up 172% year-to-date and 716% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 68% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 42%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/microsoft-loses-exclusive-license-openai-models-taps-anthropic-claude/cZBNAqiRePg">Microsoft Loses Exclusive Access To OpenAI Models In Partnership Reset Ahead Of Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Oruka Therapeutics stated that 64% of the participants in the Phase 2a EVERLAST-A trial of ORKA-001 met the study’s primary endpoint.

<ul class="summary-bullets"><li>Peloton stated that, starting Monday, Spotify Premium subscribers in most countries worldwide can access a curated selection of fitness content.</li><li>This includes strength, pilates, barre, yoga, stretching, meditation, floor cardio and outdoor classes.</li><li>The company stated that the library features sessions in English, Spanish and German, led by a roster of popular instructors, with new classes and formats added regularly.</li></ul>Peloton Interactive Inc. (PTON) on Monday announced a partnership with Spotify Technology SA (SPOT) to bring its fitness content to the music streaming giant’s 290 million subscribers.The partnership between the two companies is part of Spotify’s plans to ramp up the offerings in its new fitness category. This also gives Peloton’s fitness content the exposure to hundreds of millions of Spotify subscribers around the world, helping the company elevate itself from a fitness equipment maker to a fitness content provider.<a href="https://stocktwits.com/symbol/PTON">Peloton shares</a> were up nearly 7% in Monday’s pre-market trade, on track for the biggest gains in this month so far. PTON was among the top trending tickers on the platform at the time of writing.<h2 class="st-heading-2">From Pilates To Yoga And More</h2>Peloton stated that starting Monday, Spotify Premium subscribers across most countries in the world can access a curated selection of Strength, Pilates, Barre, Yoga, Stretching, Meditation, Floor Cardio and Outdoor classes in Spotify’s new Fitness category.The company stated that the library features sessions in English, Spanish and German, led by a roster of popular instructors, with new classes and formats added regularly.“By bringing Peloton directly into our video and audio ecosystem, we are investing in a future where Spotify isn’t just where you spend your time—it’s where you go to build momentum, improve your wellbeing, and get more out of every day,” said Roman Wasenmüller, VP, Global Head of Podcasts, Spotify.Peloton also stated that this partnership underscores its shift toward a more diversified business model.“With this partnership, we are instantly activating a global footprint that makes the magic of Peloton accessible to Spotify Premium subscribers anywhere,” said Peloton’s Chief Commercial Officer, Dion Camp Sanders.Spotify currently has 751 million users and 290 million subscribers in 184 countries.<h2 class="st-heading-2">Trump Tariff Impact On Peloton</h2>According to TheFly, analysts at UBS stated earlier this month that the Section 232 tariff changes will reduce the levies on aluminum that Peloton uses for its equipment to 25% from 50%.The firm maintained its ‘Buy’ rating on PTON stock with a $11 price target, implying an upside of more than 110% from current levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/PTON">Peloton</a> trended in the ‘neutral’ territory, with message volumes at ‘high’ levels at the time of writing.One user thinks that Peloton’s market capitalization should be no less than $20 billion, while it is currently hovering around $2.2 billion.<stembedurl>https://stocktwits.com/DORITOBOI/message/651488886</stembedurl><a href="https://stocktwits.com/symbol/PTON">PTON stock</a> is down 16% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/SPOT">SPOT stock</a> is down 11%. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 31% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 43%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ntla-stock-soars-intellia-positive-gene-therapy-trial/cZBNFouRe2C">NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Peloton bike is displayed at a Dick's Sporting Goods store on May 08, 2024 in Daly City, California. (Photo by Justin Sullivan/Getty Images)

Peloton’s Spotify Deal Opens Doors To 290M Users: PTON Stock On Track For Best Gains This Month

The partnership between the two companies is part of Spotify’s plans to ramp up the offerings in its new fitness category.

iShares Trust - iShares Russell 2000 Index Fund

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Stocktwits

Stocktwits Polls

iShares Russell 2000 ETF

Traders are aggressively debating whether the relentless market rally to all-time highs is a genuine structural shift or a fragile, liquidity-fueled bubble.

Market participants are fixated on the evolving conflict in the Strait of Hormuz, linking military updates to aggressive price action across major indices.

Large-scale institutional hedging through heavy put volume in the Russell 2000 has traders scanning for potential downside risks despite the ongoing bullish trend.

Investors are closely watching rotation into lagging small caps, looking for improved market breadth to sustain current momentum.

Discussions center on whether individual AI contract catalysts are driving the broader market index performance or merely masking deeper systemic volatility.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest IWM News

IWMiShares Russell 2000 ETF